KoreaTechToday - Korea's Leading Tech and Startup Media Platform
  • Topics
    • Naver
    • Kakao
    • Nexon
    • Netmarble
    • NCsoft
    • Samsung
    • Hyundai
    • SKT
    • LG
    • KT
    • Retail
    • Startup
    • Blockchain
    • government
  • Lists
KoreaTechToday - Korea's Leading Tech and Startup Media Platform
  • Topics
    • Naver
    • Kakao
    • Nexon
    • Netmarble
    • NCsoft
    • Samsung
    • Hyundai
    • SKT
    • LG
    • KT
    • Retail
    • Startup
    • Blockchain
    • government
  • Lists
KoreaTechToday - Korea's Leading Tech and Startup Media Platform
No Result
View All Result
Home Healthcare

SK’s Drug Maker Unit to Become a Globally Leading Healthcare Firm

Hayoon Kim by Hayoon Kim
PUBLISHED: July 5, 2021 UPDATED: July 6, 2021
in Healthcare, SK, Tech Industry
0
SK’s drug-making unit SK Biopharmaceuticals revealed its target to become one of the world’s market-leading healthcare technology developers and providers.
SK’s drug-making unit SK Biopharmaceuticals revealed its target to become one of the world’s market-leading healthcare technology developers and providers.

SK’s drug-making unit SK Biopharmaceuticals revealed its target to become one of the world’s market-leading healthcare technology developers and providers.

SK Group’s SK Biopharmaceuticals Co. shared that it plans to land a leading position among the world’s top healthcare companies. Moreover, the innovative next-gen drug developer aims to achieve the goal by 2030, with its enterprise value hitting 50 trillion won ($44 billion).

During SK’s company-wide “Financial Story” online event, SK Biopharmaceuticals announced its long-term plan to expand its business scope. Currently, the company develops epilepsy-focused medications.

Previously in May 2020, SK Biopharmaceuticals developed Cenobamate, a medicine treating partial epileptic seizure onsets. In the US, it distributed the drug under the brand name Xcopri. The company also released the drug to Germany in June this year.

Developing New Treatment for Neurological Conditions

For its newest objective, the SK unit would also manufacture medication for mental disorders, rare neurological conditions, and even cancer. SK Biopharmaceuticals CEO Cho Jeong-Woo stated that SK Biopharmaceuticals’ would introduce brand new products optimized for treating rare neurological diseases before 2025.

CEO Cho also said that the company is also researching medications for a broad range of mental disorders. To this end, SK Biopharmaceuticals strategically teamed up with pharmaceutical companies across various Asian and European markets.

Furthermore, CEO Cho revealed that the drug developer and researcher would increase its marketing efforts twofold. In particular, SK Biopharmaceuticals would strengthen operations globally and in the US. As a result, its corporate value could reach 25 trillion won ($23 billion) after five years.

During 2021’s first quarter, SK Biopharmaceuticals’ overall sales rose to 140 billion won from the previous 3.9 billion won, increasing over thirty-six times. Notably, this figure is a significant increase from the company’s record in the same period a year earlier.

Strengthening Company Capacity

SK Biopharmaceuticals also plans to introduce new drugs for central nervous system treatment across the US market. As part of this goal, the company would invest more in research and development. It would also increase funding for drug candidate scouting.

According to the drug maker, it plans to accelerate its digital transformation by utilizing artificial intelligence in drug development operations. SK Biopharmaceuticals would also employ RNA-based drug technologies to create treatments and medication.

Meanwhile, SK Biopharmaceuticals’ latest sustainable development report indicated that it has actively reinforced its ESG management drive. The drugmaker also plans to meet SK Group’s carbon neutrality vision.

Recently, SK Group announced that it would achieve carbon neutrality before the UN-passed 2050 target.

Check out other must-read articles from KoreaTechToday:

  • KT Develops Next-Gen Neuro-Electronic Therapy Tech with NeuroSigma
  • HCI Tech Startup Impressivo to Unite Fitness and Healthcare Solutions
  • AI Medical Tech Startup VUNO Enhances Samsung’s X-ray System
  • Samsung Promotes AI Healthcare Startups with Ada Health Investment
Tags: drugdrug developerhealthcaremedicineSK BiopharmacueticalsSK Group

Related Posts

Inside Stargate: How Samsung and SK Are Powering OpenAI’s Global AI Ambitions
SK’s drug-making unit SK Biopharmaceuticals revealed its target to become one of the world’s market-leading healthcare technology developers and providers.
AI

Inside Stargate: How Samsung and SK Are Powering OpenAI’s Global AI Ambitions

October 7, 2025
South Korea Prepares Fourth Launch of Homegrown Nuri Rocket
SK’s drug-making unit SK Biopharmaceuticals revealed its target to become one of the world’s market-leading healthcare technology developers and providers.
Government

South Korea Prepares Fourth Launch of Homegrown Nuri Rocket

October 1, 2025
SK Telecom Commits $3.6B to AI with New Company-in-Company Unit
SK’s drug-making unit SK Biopharmaceuticals revealed its target to become one of the world’s market-leading healthcare technology developers and providers.
AI

SK Telecom Commits $3.6B to AI with New Company-in-Company Unit

September 29, 2025
South Korea, BlackRock Team Up to Build Hyperscale AI Data Center Hub
SK’s drug-making unit SK Biopharmaceuticals revealed its target to become one of the world’s market-leading healthcare technology developers and providers.
Data Center

South Korea, BlackRock Team Up to Build Hyperscale AI Data Center Hub

October 1, 2025
LG and SK Join Forces on AI Data Center Cooling and Energy Solutions
SK’s drug-making unit SK Biopharmaceuticals revealed its target to become one of the world’s market-leading healthcare technology developers and providers.
AI

LG and SK Join Forces on AI Data Center Cooling and Energy Solutions

September 25, 2025
Samsung AI Forum 2025: Could its AI Agents Change How We Interact with Technology?
SK’s drug-making unit SK Biopharmaceuticals revealed its target to become one of the world’s market-leading healthcare technology developers and providers.
AI

Samsung AI Forum 2025: Could its AI Agents Change How We Interact with Technology?

September 25, 2025
No Result
View All Result

Most Popular

  • Ride-Hailing Rivalry: Kakao and Uber Bet on Membership Services in Korea

    0 shares
    Share 0 Tweet 0
  • Kakao Mobility Faces $10.5 Million Fine for Limiting Competitors’ Access to Taxi Platform

    0 shares
    Share 0 Tweet 0
  • Korea’s Navigation Battle Heats Up: Naver and Kakao vs. Google maps

    0 shares
    Share 0 Tweet 0
  • 5 Best Korean to English Translation Apps

    0 shares
    Share 0 Tweet 0
  • Naver Launches 3D Street View for Immersive Navigation Experience

    0 shares
    Share 0 Tweet 0
  • KakaoTalk to Adopt Instagram-Style Feed in Major 2025 Redesign

    0 shares
    Share 0 Tweet 0
  • Naver Maps Launches Guide in English, Chinese, and Japanese to Enhance Travel Experience for Tourists

    0 shares
    Share 0 Tweet 0
  • Top Nine Mobile MMORPG in South Korea for 2020

    0 shares
    Share 0 Tweet 0
  • Naver Unveils Asia’s Largest Data Center, GAK Sejong, for Tech Innovation

    0 shares
    Share 0 Tweet 0
  • South Korea Invests $1.1B to Build National AI GPU Infrastructure

    0 shares
    Share 0 Tweet 0

PRODUCTS

[ads_amazon]

TOPICS

  • Naver
  • Kakao
  • Nexon
  • Netmarble
  • NCsoft
  • Samsung
  • Hyundai

FREE NEWSLETTER

FOLLOW US

  • About Us
  • Cookie policy
  • home
  • homepage
  • mainhome
  • Our Services
  • Privacy Policy
  • Terms of Use

Copyright © 2024 KoreaTechToday | About Us | Terms of Use |Privacy Policy |Cookie Policy| Contact : [email protected] |

No Result
View All Result
  • Topics
    • Naver
    • Kakao
    • Nexon
    • Netmarble
    • NCsoft
    • Samsung
    • Hyundai
    • SKT
    • LG
    • KT
    • Retail
    • Startup
    • Blockchain
    • government
  • Lists

Copyright © 2024 KoreaTechToday | About Us | Terms of Use |Privacy Policy |Cookie Policy| Contact : [email protected] |